Early Stage
Search >>
Eurofins ADME BIOANALYSES services span the complete drug development cycle for new chemical entities (NCE), biologics and generics.
![](https://cdnmedia.eurofins.com/corporate-eurofins/media/lybfwxpu/our-services.png?width=763&height=327)
Early Stage
It is in the early stages of development that reliable information is required with a quick response time and at a competitive price.
Eurofins ADME Bioanalyses offers a range of services in-house to aid in the decision making process from first “in-life” studies to compare products and formulations to in-vivo and in-vitro metabolism studies.
We have the capacity to manage studies on large, molecules, small molecules and ADC with all conventional and novel delivery systems.
Small molecule bioanalysis
- Any biological matrix (fluids and tissues)
- Supporting screening, pre-clinical exploratory/safety and clinical studies
- Small molecules (LC-MS/MS)
- Method development, transfer and/or optimization
- Fit for purpose method qualification & validation
- More than 1000 in-house validated methods
- GLP and GcLP compliant
Large molecule bioanalysis
- Diverse biological matrix (fluids and tissues)
- Supporting early, pre-clinical exploratory/safety and clinical studies
- Large molecules - ELISA / ECL (Mesoscale)
- Method development, transfer and/or optimization
- Fit for purpose method qualification & validation
- GLP and GcLP compliant
Topical product development
- IVRT/IVPT for generic product development
- In vitro / In vivo application of topical products
- Franz diffusion cells, Bronaugh diffusion cells, PhoenixTM Dry Heat system
- Skin distribution with radiolabelled (14C/3H) or cold compound
- Clinical dermal absorption, tape stripping, PK and Bioequivalence
- Bioanalytical method, development and validation for skin matrices
- Cosmetics, Pharmaceuticals, Safety Testing, formulations comparisons
- GLP compliant, OECD 428, SCCS guidelines
Screening studies
- Non-GLP, all phases in-house, adaptable study design for lead selection
- Exploratory PK blood-brain barrier, tissue distribution, CSF
- Calculation of Cmax, Tmax, AUC, t½ , Cl, Vd, Bioavailability (F%), tissue exposure etc.
- Different rodent species, single or cassette dosing, all administration routes
- Microsampling:PK profile on the same animal
- Only a small quantity of compound is required
- Standardised LC-MS/MS analytical development
- Rapid response: <2 weeks from agreement to study start
- Rapid turn-around: <2 weeks from reception of product to table of results
- Aggressive pricing policy to keep down development costs